


Express Mail No.: EH959258369US
Date of Deposit: September 2, 1999

CP. 1643

PATENT APPLICATION
Attorney Dock t No.: CURA-18 (15966-518)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Mehta *et al.*
ASSIGNEE: CuraGen Corporation
SERIAL NUMBER: 09/351,617
FILING DATE: July 12, 1999
TITLE: GENERAL SCREENING METHOD FOR LIGAND-PROTEIN INTERACTIONS



Examiner: Not Assigned
Art Unit: 1643

#5
Lad
3/4/00

September 2, 1999
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Sir:

Transmitted herewith for filing in the present application are the following documents:

- ☒ Information Disclosure Statement
- ☒ PTO Form 1449
- ☒ Copies of 4 U.S. Patent Documents, 5 Foreign Patent Documents, and 27 Non Patent Literature Documents.
- ☒ Post Card

The Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 15966-518. A duplicate copy of this Transmittal is enclosed.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (617) 542-6000, Boston, Massachusetts.

Respectfully submitted

Ivor R. Elrifi, Registration No. 39,529
Shelby J. Walker, Registration No. P45,192
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

TRADOCS: 1233568.1 (qfts011.doc)

RECEIVED

SEP 07 1999

TECH CENTER 1600/2900

Express Mail Label No. EH959258836US

Date of Deposit: September 2, 1999

Attorney Docket No. 15966-518

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Mehta et al.
ASSIGNEE : CuraGen Corporation
SERIAL NUMBER : 09/351,617
FILING DATE : July 12, 1999
FOR : GENERAL SCREENING METHOD FOR LIGAND-PROTEIN INTERACTIONS

EXAMINER : Not Assigned
ART UNIT : 1643



August , 1999
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

U.S. Patent Documents:

Fields	5,468,614	Issued 11/21/95
Gut	5,469,285	Issued 11/21/95
Crabtree	5,871,753	Issued 2/16/99
Liu	5,928,868	Issued 7/27/99

Foreign Patent Documents:

Fowlkes	WO 94/23025
Broach	WO 95/30012
Crabtree	WO 95/02684
Schreiber	WO 96/13613
Holt	WO 96/06097

Other Prior Art – Non Patent Literature Documents:

Abramson *et al.*, J MED CHEM, **34** (6), 1798-804 (1991).
Ausubel, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY CHAPTER 9.
Boopathy *et al.*, BIOCHEM J., **239** (2), 371-7 (1986).
Born *et al.*, J. BIOL CHEM, **270** (43), 25651-5 (1995).

Durfee *et al.*, GENES AND DEVELOPMENT, 7, 555-569 (1993).
Edwards *et al.*, J MED CHEM, 38 (1), 76-85 (1995).
Goodman *et al.*, THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, (1996).
Griffin *et al.*, SCIENCE, 281 (5374), 269-72 (1998).
Hanzlik *et al.*, BIOCHIM BIOPHYS ACTA, 1035(1), 62-70 (1990).
Li *et al.*, J STEROID BIOCHEM, 36 (6), 533-9 (1990).
Licitra *et al.*, PROC NATL ACAD SCI USA, 93 (23), 12817-21 (1996).
March, ADVANCED ORGANIC CHEMISTRY, (1972).
Mendelsohn *et al.*, CURR OPIN BIOTECHNOL, 5 (5), 482-486 (1994).
Michels *et al.*, TRENDS, 16 (5), 210-5 (1998).
Mueller *et al.*, PROC NATL ACAD SCI USA, 92 (18), 8383-7 (1995).
O'Brien *et al.*, J NEURAL TRASM SUPPL, 41, 295-305 (1994).
Pruschy, CHEM BIOL, 1, 163-172 (1994).
Roth *et al.*, J BIOL CHEM, 253 (11), 3782-4 (1978).
Salto *et al.*, 269 (14), 10691-8 (1994).
Schenkein *et al.*, J BIOL CHEM, 255 (1), 45-8, (1980).
Silverman, METHODS ENZYMOL, 249, 240-83 (1995).
Singh *et al.*, J MED CHEM, 40 (7), 1130-5 (1997).
Snider *et al.*, J STEROID BIOCHEM, 22(3), 325-30 (1985).
Tous *et al.*, J MED CHEM, 33(6), 1620-34 (1990).
Yang *et al.*, NUCLEIC ACIDS RES, 23 (7), 1152-6 (1995).
Zaugg *et al.*, J BIOL CHEM, 255 (7), 2816-21 (1980).
Zhang *et al.*, J MED CHEM, 40(1), 4-8 (1997).

This Information Disclosure Statement is being filed:

- ☒ within three months of the filing date of the National Application.
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application.
- ☐ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or

that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Shelby J. Walker, Reg. No. P45,192
Attorney(s) for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: September 2, 1999